Indications |
Oral HIV infection Adult: Combined with other antiretrovirals: 300 mg bid or 600 mg once daily. Child: Combined with other antiretrovirals: >3 mth: 8 mg/kg bid. Max: 600 mg daily. Renal impairment: Avoid in end stage renal disease. Hepatic impairment: Child pugh category A: 200 mg bid. Avoid in moderate-severe impairment. |
Contraindications |
Moderate to severe renal and hepatic impairment; end stage renal disease; history of hypersensitivity reactions. Pregnancy and lactation. |
Warnings / Precautions |
Renal or mild liver impairment; risk for liver impairment. Discontinued when hepatomegaly and unexplained metabolic acidosis develops, or liver function deteriorates. May impair ability to drive or engage in tasks requiring alertness. Discontinue treatment as soon as hypersensitivity is suspected. |
Adverse Reactions |
Anorexia, headache, nausea, vomiting, diarrhoea, rash, fever, cough, dyspnoea, fatigue, malaise, lethargy, abdominal pain. Pancreatitis and elevated blood glucose and TG concentrations. Potentially Fatal: Severe hypersensitivity reactions. |
Drug Interactions |
Alcohol may cause decreased elimination of abacavir. Lactic acidosis with nucleoside analogues concomitantly. Decreased serum concentrations of methadone. See Below for More abacavir Drug Interactions |
Mechanism of Actions |
Abacavir is converted to the active form carbovir triphosphate intracellularly. It competitively inhibits the reverse transcriptase of retroviruses interfering with HIV viral RNA-dependent DNA polymerase resulting in inhibition of viral replication. Absorption: Rapidly absorbed after oral administration with an oral bioavailability of about 80%. Distribution: 50% bound to plasma proteins. Crosses the blood brain barrier. Metabolism: Undergoes intracellular metabolism to carbovir triphosphate which is the active metabolite. Excretion: Elimination half-life: About 1.5 hr after a single oral dose. Elimination by hepatic metabolism mainly by alcohol dehydrogenase and glucuronidation. The metabolites are excreted mainly in the urine. |
Administration |
May be taken with or without food. |
Storage Conditions |
Oral: Store at 20-25°C. |
ATC Classification |
J05AF06 - abacavir ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections. |
Storage |
Oral: Store at 20-25°C. |
Available As |
|
Abacavir
Post Review about Abacavir Click here to cancel reply.
Abacavir Containing Brands
Abacavir is used in following diseases
Drug - Drug Interactions of Abacavir
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.